A phase IV open-label evaluation of safety and tolerability of coformulated bictegravir/emtricitabine/tenofovir alafenamide for post-exposure prophylaxis following potential exposure to HIV-1

A. Liu,R. Xin, H. Zhang,L. Dai, R. E. Wu, X. Wang,A. Li,J. Li,Y. Shao, Y. Gao, Z. Wang,J. Ye, G. Abudourexiti,Z. Li,L. Sun

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY（2022）

Cited 0|Views25

No score

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined